MBIO - Mustang Bio Inc logo

MBIO

Mustang Bio Inc

Rev โ€”top 1%5Y
Hold

Mustang Bio develops cell and gene therapies targeting difficult-to-treat cancers and autoimmune diseases. Its pipeline includes CAR T cell therapies for non-Hodgkin lymphoma and glioblastoma, and oncolytic virus treatments for herpes simplex virus-1.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth87.80%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth96.80%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth93.86%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Mustang Bio Inc fundamental performance

Across Mustang Bio Inc's full reported history, from 2017 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 31M to -$ 1M. Revenue increased in 0% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.61โ€”
1 Year2025-08-12
$ 1.70-64.39%
5 Years2021-08-12
$ 2.09K-99.97%
All Time2017-08-22
$ 7.35K-99.99%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 0.00-$ 1M$ 17M
2024$ 0.00-$ 15M$ 6M
2023$ 0.00-$ 51M$ 6M
2022$ 0.00-$ 77M$ 75M
2021$ 0.00-$ 66M$ 109M
2020$ 0.00-$ 60M$ 97M
2019$ 0.00-$ 48M$ 61M
2018$ 0.00-$ 30M$ 34M
IPO2017$ 0.00-$ 31M$ 60M

Explore beyond MBIO

You're looking at Mustang Bio Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies